Condition
Anemia of End Stage Renal Disease
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Completed2
Terminated2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01719146CompletedPrimary
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
NCT02468414Phase 2TerminatedPrimary
TARGTEPO Treatment for Anemia in PD US Trial
NCT02378662Phase 2TerminatedPrimary
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
NCT02049346Phase 4CompletedPrimary
Comparison Among Erythropoietin Stimulating Agents
Showing all 4 trials